AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8240151 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg daily, titrated to 40 mg daily
Number of subjects: 48
Study 8240151 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg daily, titrated to 40 mg daily
Number of subjects: 48
Study 8240151 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (after switching from pravastatin)
Number of subjects: 48
Study 3549809 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% topical minoxidil
Number of subjects: 30
Study 3549809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29099727 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental computational phantoms and dose‐calculation models
Number of subjects: 9
Study 26923704 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte linoleic acid (LA)
Number of subjects: 139
Study 26923704 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte oleic acid (OA)
Number of subjects: 139
Study 26923704 — intervention group
Group type: COMPARATOR
Intervention: Erythrocyte long chain omega-3 fatty acids (LC-Ω3-SUM)
Number of subjects: 139
Study 24729041 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (4.5 mg/m²/day)
Number of subjects: 44
Study 24729041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22951490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) 25 mg once daily
Number of subjects: 1796
Study 22951490 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once daily
Number of subjects: 1796
Study 22951490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V90I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V90I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V106I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V106I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V179I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V179I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) with V189I mutation
Number of subjects: 1796
Study 22951490 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) with V189I mutation
Number of subjects: 1796
Study 21049089 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5-20 mg/day
Number of subjects: 1062
Study 21049089 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 2-20 mg/day
Number of subjects: 1062
Study 21049089 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 2-10 mg/day
Number of subjects: 1062
Study 21049089 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 80-160 mg/day
Number of subjects: 1062
Study 21049089 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1062
Study 18284439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with venlafaxine for 2 years
Number of subjects: 0
Study 18284439 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with venlafaxine
Number of subjects: 0
Study 18284439 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study 16024406 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental program 'Taking Care of Myself' (EG)
Number of subjects: 137
Study 16024406 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison program offered by an Alzheimer Society (AG)
Number of subjects: 137
Study 16024406 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 137
Study 12529349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day, N = 2700
Number of subjects: 5408
Study 12529349 — intervention group
Group type: COMPARATOR
Intervention: Placebo, N = 2708
Number of subjects: 5408
Study 12529349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, high-risk group
Number of subjects: 5408
Study 12529349 — intervention group
Group type: COMPARATOR
Intervention: Placebo, high-risk group
Number of subjects: 5408
Study 12529349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, low-risk group
Number of subjects: 5408
Study 12529349 — intervention group
Group type: COMPARATOR
Intervention: Placebo, low-risk group
Number of subjects: 5408
Study 12529349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen, ER+ tumors, high-risk group
Number of subjects: 5408
Study 12529349 — intervention group
Group type: COMPARATOR
Intervention: Placebo, ER+ tumors, high-risk group
Number of subjects: 5408
Study 10541421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 880 microg/day
Number of subjects: 30
Study 8759815 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril therapy
Number of subjects: 0
Study 8759815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1806734 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg of ASA
Number of subjects: 17
Study 1806734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6859372 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum antisperm antibody titer of 512 or more
Number of subjects: 130
Study 6859372 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum antisperm antibody titer below 512
Number of subjects: 130
Study 6859372 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of seminal plasma antibodies (titers up to 16)
Number of subjects: 130
Study 6859372 — intervention group
Group type: COMPARATOR
Intervention: Perioperative steroids (randomized controlled trial)
Number of subjects: 130
Study 31192254 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 142
Study 31192254 — intervention group
Group type: EXPERIMENTAL
Intervention: Forns
Number of subjects: 142
Study 31192254 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB-4
Number of subjects: 142
Study 31192254 — intervention group
Group type: EXPERIMENTAL
Intervention: GAPRI
Number of subjects: 142
Study 31192254 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepascore
Number of subjects: 142
Study 31192254 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-Platelet
Number of subjects: 142
Study 29105045 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 60
Study 29105045 — intervention group
Group type: COMPARATOR
Intervention: Standard weight-control programme
Number of subjects: 60
Study 27189190 — intervention group
Group type: EXPERIMENTAL
Intervention: Podiatry treatment
Number of subjects: 46
Study 27189190 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA)
Number of subjects: 46
Study 27189190 — intervention group
Group type: COMPARATOR
Intervention: Potassium hydroxide (KOH, 40%)
Number of subjects: 46
Study 24475111 — intervention group
Group type: EXPERIMENTAL
Intervention: 110% relative to the resting motor threshold (rMT)
Number of subjects: 36
Study 24475111 — intervention group
Group type: EXPERIMENTAL
Intervention: 120% relative to the resting motor threshold (rMT)
Number of subjects: 36
Study 24475111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stimulation intensities (110% rMT and 120% rMT)
Number of subjects: 36
Study 24475111 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rMT subjects
Number of subjects: 36
Study 21960086 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 14
Study 21960086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19913984 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with manikin-DVD set facilitated by high school students
Number of subjects: 4
Study 19913984 — intervention group
Group type: COMPARATOR
Intervention: Pre-training
Number of subjects: 4
Study 17625280 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy and magnification endoscopy
Number of subjects: 15
Study 17625280 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 15
Study 16311460 — intervention group
Group type: EXPERIMENTAL
Intervention: New apparatus for performing infusion tests in a standardized and automated way
Number of subjects: 14
Study 12372312 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 20
Study 12372312 — intervention group
Group type: COMPARATOR
Intervention: No-tape condition
Number of subjects: 20
Study 9706941 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCO2 of 25 mm Hg
Number of subjects: 7
Study 9706941 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCO2 of 45 mm Hg
Number of subjects: 7
Study 7705113 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Inspiratory Muscle Training (SIMT)
Number of subjects: 12
Study 7705113 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 12
Study 2612300 — intervention group
Group type: COMPARATOR
Intervention: 25 mg ALEC powder
Number of subjects: 459
Study 2612300 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of 100 mg ALEC suspension
Number of subjects: 459
Study 2612300 — intervention group
Group type: COMPARATOR
Intervention: ALEC treatment
Number of subjects: 459
Study 619513 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 0
Study 619513 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 0
Study 31556975 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 207
Study 31556975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 27317843 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IGFBP7 (BL-IGFBP7)
Number of subjects: 302
Study 27317843 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month change in IGFBP7 (ΔIGFBP7) in patients randomized to irbesartan
Number of subjects: 302
Study 27317843 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP7 concentrations
Number of subjects: 302
Study 26244854 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered Cognitive Behavioral Therapy (CBT)
Number of subjects: 141
Study 26244854 — intervention group
Group type: COMPARATOR
Intervention: Telephone-delivered Nondirective Supportive Therapy (NST)
Number of subjects: 141
Study 23555980 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarials plus antibiotics
Number of subjects: 667
Study 23555980 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarials only (intervention arm)
Number of subjects: 667
Study 23555980 — intervention group
Group type: COMPARATOR
Intervention: Antimalarials only (control arm)
Number of subjects: 667
Study 22451889 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithalamin (peptide drug), 6 courses over 3 years
Number of subjects: 79
Study 22451889 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy alone (Control)
Number of subjects: 79
Study 19781465 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% drops 4 times a day for 1 day
Number of subjects: 120
Study 19781465 — intervention group
Group type: COMPARATOR
Intervention: Topical moxifloxacin 0.5% drops 4 times a day for 3 days
Number of subjects: 120
Study 16400044 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg Ca/d as calcium carbonate)
Number of subjects: 110
Study 16400044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15302007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet for 15 days
Number of subjects: 24
Study 15302007 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 24
Study 11406341 — intervention group
Group type: COMPARATOR
Intervention: Basal intravenous infusion of saline solution with verbal instructions of a powerful painkiller (double-blind administration)
Number of subjects: 3
Study 11406341 — intervention group
Group type: COMPARATOR
Intervention: Basal intravenous infusion of saline solution with verbal instructions of a potent painkiller (deceptive administration)
Number of subjects: 3
Study 11406341 — intervention group
Group type: COMPARATOR
Intervention: Basal intravenous infusion of saline solution with no verbal instructions (natural history)
Number of subjects: 3
Study 9226591 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 1200 mg
Number of subjects: 6
Study 8095149 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg noberastine
Number of subjects: 12
Study 8095149 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg noberastine
Number of subjects: 12
Study 8095149 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg noberastine
Number of subjects: 12
Study 8095149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3481038 — intervention group
Group type: COMPARATOR
Intervention: Conventional intrathecal methotrexate therapy with cranial irradiation
Number of subjects: 36
Study 3481038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate regimen (10 courses of 33,600 mg/m2 over 24 hours, with high-dose leucovorin rescue)
Number of subjects: 36
Study 29072551 — intervention group
Group type: EXPERIMENTAL
Intervention: REbeL program
Number of subjects: 71
Study 29072551 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 26160254 — intervention group
Group type: EXPERIMENTAL
Intervention: 7000-IU/d vitamin D3 supplementation
Number of subjects: 58
Study 26160254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 24801056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 20
Study 24801056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 22127572 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI)
Number of subjects: 12
Study 22127572 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiotherapy only)
Number of subjects: 12
Study 20889945 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU bolus of oxytocin
Number of subjects: 143
Study 20889945 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 143
Study 18518727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboventricular lavage and simultaneous low-frequency head-motion therapy
Number of subjects: 40
Study 18518727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 40
Study 16377101 — intervention group
Group type: EXPERIMENTAL
Intervention: Prize-based contingency management (CM)
Number of subjects: 415
Study 16377101 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 415
Study 12784319 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg albendazole daily for 15 days
Number of subjects: 12
Study 11022182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8
Study 8630634 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg once daily
Number of subjects: 255
Study 8630634 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg
Number of subjects: 255
Study 1486669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A 30,000 RE (100,000 IU)
Number of subjects: 2840
Study 1486669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A 15,000 RE (50,000 IU)
Number of subjects: 2840
Study 1486669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (75 RE (250 IU) and 150 RE (500 IU))
Number of subjects: 2840
Study 6437268 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular piritramide
Number of subjects: 35
Study 6437268 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural with 0.125% bupivacaine
Number of subjects: 35
Study 31146579 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive dental intervention
Number of subjects: 138
Study 31146579 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study 30589005 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride mouthrinse (0.05%)
Number of subjects: 60
Study 30589005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulsi mouthrinse (4%)
Number of subjects: 60
Study 30589005 — intervention group
Group type: EXPERIMENTAL
Intervention: Black myrobalans mouthrinse (2.5%)
Number of subjects: 60
Study 26481918 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol at a dose of 2 mg/kg per day in three divided doses
Number of subjects: 64
Study 26481918 — intervention group
Group type: COMPARATOR
Intervention: Oral ibuprofen at a dose of 10 mg/kg 8-hourly and paracetamol at a dose of 16.2 mg/kg 8-hourly
Number of subjects: 64
Study 26481918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 23688125 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 273
Study 23688125 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 273
Study 22507978 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 50
Study 22507978 — intervention group
Group type: COMPARATOR
Intervention: pravastatin 20 mg/day
Number of subjects: 50
Study 19835669 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 12 weeks
Number of subjects: 44
Study 19835669 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug-free depressed patients)
Number of subjects: 44
Study 17490962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (6 g tuna FO/d, approximately 1.9 g n-3 FA)
Number of subjects: 0
Study 17490962 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (walking 3 d/wk for 45 min at 75% age-predicted maximal heart rate)
Number of subjects: 0
Study 17490962 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) and exercise
Number of subjects: 0
Study 17490962 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SO; control)
Number of subjects: 0
Study 17490962 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil and exercise (SOX)
Number of subjects: 0
Study 15716684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fiber intake
Number of subjects: 25
Study 12652153 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 89
Study 12652153 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 89
Study 10366081 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (Neuroton, 1000 mg/day intramuscularly for 60 days)
Number of subjects: 40
Study 10366081 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic solution with additives for 60 days)
Number of subjects: 40
Study 10366081 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (second 60-day treatment) in GC2 patients
Number of subjects: 40
Study 10366081 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline (after washout in GC1 patients)
Number of subjects: 40
Study 7718376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% isoflurane in oxygen for 8 min
Number of subjects: 7
Study 7718376 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen for 8 min
Number of subjects: 7
Study 1935341 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual recognition (V-V)
Number of subjects: 36
Study 1935341 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactual recognition (T-T)
Number of subjects: 36
Study 1935341 — intervention group
Group type: EXPERIMENTAL
Intervention: T-V transfer
Number of subjects: 36
Study 1935341 — intervention group
Group type: EXPERIMENTAL
Intervention: V-T transfer
Number of subjects: 36
Study 1935341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramodal transfer
Number of subjects: 36
Study 7138954 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta feedback
Number of subjects: 16
Study 7138954 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR feedback
Number of subjects: 16
Study 31609426 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid supplementation
Number of subjects: 377
Study 31609426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 29938411 — intervention group
Group type: EXPERIMENTAL
Intervention: Copal varnish
Number of subjects: 60
Study 29938411 — intervention group
Group type: COMPARATOR
Intervention: Dentin adhesive liner
Number of subjects: 60
Study 26562568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis Ball Technique (TBT)
Number of subjects: 40
Study 26562568 — intervention group
Group type: COMPARATOR
Intervention: Nonsupine Positioning (NSP) regimen without TBT
Number of subjects: 40
Study 26562568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis Ball Technique (TBT) for noncompliant participants
Number of subjects: 40
Study 24381332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.2‐0.7 µg/kg/h after a loading dose of 1 µg/kg with 1.2‐2.4 µg/kg/h of remifentanil
Number of subjects: 90
Study 24381332 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (1‐2 mg) with 3.6‐7.2 µg/kg/h of remifentanil
Number of subjects: 90
Study 24381332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-remifentanil
Number of subjects: 90
Study 21621471 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo‐loaded Diskus (supervised and assisted use)
Number of subjects: 40
Study 21621471 — intervention group
Group type: EXPERIMENTAL
Intervention: MMSE scores
Number of subjects: 40
Study 21173411 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded echinacea pills (10.2 g during the first 24 hours and 5.1 g during each of the next 4 days)
Number of subjects: 719
Study 21173411 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded echinacea pills (10.2 g during the first 24 hours and 5.1 g during each of the next 4 days)
Number of subjects: 719
Study 21173411 — intervention group
Group type: COMPARATOR
Intervention: Blinded placebo pills (indistinguishable from echinacea)
Number of subjects: 719
Study 21173411 — intervention group
Group type: COMPARATOR
Intervention: No pills
Number of subjects: 719
Study 21173411 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded echinacea pills
Number of subjects: 719